Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-17.8
%Wording
Conditional
How definitive the wording is.Results for this period
Full year2024年9月1日〜2025年8月31日ConsolidatedJapanese GAAPNet Sales29,968¥ millionYear on year +5.1%Progress 91.4%
Operating profit8,193¥ millionYear on year -2.4%Progress 89.1%
Ordinary income8,271¥ millionYear on year -2.3%Progress 92.4%
Net income attributable to owners of the parent5,167¥ millionYear on year -17.8%Progress 80.1%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥52.46
Financial position at period-end
Total assets58,537¥ million
of which net assets 54,111 ¥ million
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Cash inflows and outflows
Operating+7,017
Investment-7,154
Financials-3,895
Net change-4,032
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥17,401 million
Segment revenue
Surgical-related products9,27430.9%+13.8%
Ailess needle-related products11,18337.3%+9.4%
Dental Products9,50931.7%-6.2%
Segment profit
Surgical-related products3,08037.6%+16.6%
Ailess needle-related products4,00248.9%+3.4%
Dental Products1,11013.5%-40.9%
Regional salesThe current consolidated fiscal year Japan ¥4,871 million / North America ¥2,909 million / Europe ¥5,721 million / Asia ¥13,426 million / Other ¥3,038 million / Previous consolidated fiscal year Japan ¥4,206 million / North America ¥2,787 million / Europe ¥5,559 million / Asia ¥13,894 million / Other ¥2,066 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥32,800 million (YoY +9.4%)
Operating profit¥9,200 million (YoY +12.3%)
Ordinary income¥8,950 million (YoY +8.2%)
Net income¥6,450 million (YoY +24.8%)
Annual Dividend Forecast¥39 per share → ¥41 per share（+5.1%）
Factors Behind Changes in Business Performance
サージカル関連製品の眼科ナイフ販売が欧州、中国を中心としたアジア、日本、北米で拡大し、アイレス針関連製品も中国・タイを中心としたアジアや中南米等で受注が増加しました。一方、中国のマニーダイヤバー自主回収とドイツMMGの販売不調でデンタル関連製品が減収となり、決算賞与、機能強化・人員増加による販売費及び一般管理費の増加、花岡工場関連費用、MMG固定資産の減損損失1,190百万円が利益を押し下げました。
Disclosure regarding the going concern assumption
No applicable matters
Material subsequent eventsNo applicable matters.
Impairment loss¥1,190 million
Breakdown of extraordinary income (loss)Extraordinary income Insurance surrender value ¥15 million, Gain on sale of non-current assets ¥13 million / Extraordinary loss Loss on sale of fixed assets ¥1 million, Loss on Disposal of Fixed Assets ¥17 million, Impairment Losses ¥1,190 million, Other ¥3 million
Depreciation and amortization¥2,471 million
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年9月1日〜2025年8月31日 |
| Net Sales | ¥29,968 million (YoY +5.1%) |
| Operating profit | ¥8,193 million (YoY -2.4%) |
| Ordinary income | ¥8,271 million (YoY -2.3%) |
| Profit attributable to owners of the parent | ¥5,167 million (YoY -17.8%) |
| Net income per share | ¥52.46 |
| Total assets | ¥58,537 million |
| Net assets | ¥54,111 million |
| Cash flows from operating activities | ¥7,017 million |
| Cash flows from investing activities | ¥-7,154 million |
| Cash flows from financing activities | ¥-3,895 million |
| Cash and cash equivalents at end of period | ¥17,401 million |
| Full-year earnings forecast | Net Sales ¥32,800 million (YoY +9.4%) / Operating profit ¥9,200 million (YoY +12.3%) / Ordinary income ¥8,950 million (YoY +8.2%) / Net income ¥6,450 million (YoY +24.8%) |
| Annual Dividend Forecast | ¥39 per share → ¥41 per share（+5.1%） |
| Segment revenue | Surgical-related products ¥9,274 million (YoY +13.8%) / Ailess needle-related products ¥11,183 million (YoY +9.4%) / Dental Products ¥9,509 million (YoY -6.2%) |
| Segment profit | Surgical-related products ¥3,080 million (YoY +16.6%) / Ailess needle-related products ¥4,002 million (YoY +3.4%) / Dental Products ¥1,110 million (YoY -40.9%) |
| Regional sales | The current consolidated fiscal year Japan ¥4,871 million / North America ¥2,909 million / Europe ¥5,721 million / Asia ¥13,426 million / Other ¥3,038 million / Previous consolidated fiscal year Japan ¥4,206 million / North America ¥2,787 million / Europe ¥5,559 million / Asia ¥13,894 million / Other ¥2,066 million |
| Depreciation and amortization | ¥2,471 million |
| Impairment loss | ¥1,190 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Insurance surrender value ¥15 million, Gain on sale of non-current assets ¥13 million / Extraordinary loss Loss on sale of fixed assets ¥1 million, Loss on Disposal of Fixed Assets ¥17 million, Impairment Losses ¥1,190 million, Other ¥3 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Material subsequent events | No applicable matters. |
| Factors Behind Changes in Business Performance | サージカル関連製品の眼科ナイフ販売が欧州、中国を中心としたアジア、日本、北米で拡大し、アイレス針関連製品も中国・タイを中心としたアジアや中南米等で受注が増加しました。一方、中国のマニーダイヤバー自主回収とドイツMMGの販売不調でデンタル関連製品が減収となり、決算賞与、機能強化・人員増加による販売費及び一般管理費の増加、花岡工場関連費用、MMG固定資産の減損損失1,190百万円が利益を押し下げました。 |
Items this document does not state (12)
Operating MarginEquity ratioRevision to Earnings ForecastPayout ratioShareholder Return PolicyOrders received and order backlogChange in accounting policyChanges in the scope of consolidationAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.サージカル関連製品やアイレス針関連製品の販売・受注が増加した一方、中国でのマニーダイヤバー自主回収とドイツMMGの販売不調によりデンタル関連製品が減収となりました。営業利益は決算賞与、営業・開発・コーポレート機能の強化、国内人員増加に伴う販売費及び一般管理費の増加で減益となり、最終利益はMMGの固定資産減損損失1,190百万円の計上により減少しました。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.